Abiopharma

🔍 TAHL CINDY (Executive)

Company: FATE THERAPEUTICS INC (FATE)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Sold 10,589 shares of Common Stock at $1.0648 per share (Direct)
  Date: 2026-01-09 | Code: S | equity_swap_involved: false | shares_owned_after: 387,081.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 17,500 shares of Common Stock underlying RSUs granted to the Reporting Person on January 15, 2025 and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.
• F2: Represents the weighted average sale price of the shares sold ranging from $1.05 to $1.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
• REMARKS: Chief Legal and Compliance Officer